Home › Atherosclerosis › Texas

Pag-aaral pangklinika para sa Atherosclerosis sa Texas

11 pag-aaral para sa Atherosclerosis ang naghahanap ng mga kalahok sa mga site sa Texas.

Mga Lungsod sa Texas

Opisyal na teksto ng pag-aaral (English)

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

Southwest Family Medicine Associates, Dallas
East Texas Cardiology PA, Houston
Cardiovascular Specialists of Willowbrook, Houston
at 1 pa

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07448038

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

PharmaTex Research, Amarillo
St. David's Heart & Vascular PLLC dba Austin Heart, Austin
Velocity Clinical Research, Austin, Austin
at 18 pa

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT07157774

A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

PharmaTex Research, LLC, Amarillo
Pulse Care Heart and Vascular, Carrollton
DM Clinical Research - Dallas, Tomball

Nagre-recruitPhase 2

Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07521007

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Horizon Clinical Research Group, Cypress
Cardiovascular Specialists of Willowbrook, Houston
Texas Cardiology Associates of Houston, Kingwood
at 2 pa

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07783802

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

PharmaTex Research, LLC, Amarillo
Austin Heart, Austin
Velocity Clinical Research - Austin, Austin
at 22 pa

Nagre-recruitPhase 3

Edad 45 hanggang 99 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07037433

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

Cussimanio Research Group LLC, Austin
Research Management, Inc., Austin
MW Clinical Research Center, Beaumont
at 22 pa

Nagre-recruitPhase 2/3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT05485961

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

Research Site, Amarillo
Research Site, Beaumont
Research Site, Brownsville
at 33 pa

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT07000357

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

PharmaTex Research LLC, Amarillo
Kelsey Seybold Research Foundation, Houston
Northwest Houston Clinical Research PLLC, Tomball

Nagre-recruitPhase 3

Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT06813911

Pelacarsen Roll-over Extension Program

Plano Primary Care Clinic, Allen
Pharma Tex Research, Amarillo
SW Family Medicine Associates, Dallas
at 8 pa

Nagre-recruitPhase 3

Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Hul 29, 2026 · NCT06875973

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas
Michael E. DeBakey VA Medical Center, Houston, TX, Houston

Nagre-recruitPhase 4

Edad 18 pataas · Lahat ng kasarian · Na-update Dis 17, 2025 · NCT02915198

Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)

UT Health Houston, Houston

Nagre-recruitPhase 2

Edad 40 pataas · Lahat ng kasarian · Na-update Dis 17, 2025 · NCT05488431

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.